Can Tocilizumab Decrease Cartilage Oligomeric Matrix Protein Levels and Disease Activity in Patients with...

Area of Science:

• Rheumatology
• Immunology
• Biochemistry

Background:

• Serum cartilage oligomeric matrix protein (COMP) is a marker of joint destruction in rheumatoid arthritis (RA).
• Evaluating tocilizumab's (TCZ) effect on COMP levels is crucial for understanding its impact on RA progression.
• Assessing TCZ's efficacy in patients refractory to anti-TNF or DMARDs is important for treatment strategies.

Purpose of the Study:

• To evaluate the effect of TCZ on serum COMP levels in RA patients.
• To compare TCZ's effect on COMP levels between patients who failed anti-TNF treatment and those who failed DMARDs.
• To assess TCZ's impact on inflammatory markers and disease activity.

Main Methods:

• Fifty-one RA patients unresponsive to DMARDs and anti-TNF drugs received TCZ 8 mg/kg/month for six months.
• Serum COMP levels, DAS28 scores, RF (IgM, IgG, IgA), anti-CCP, ESR, CRP, and IL-6 were measured at baseline and after six months.
• Statistical analysis was performed to compare pre- and post-treatment values.

Main Results:

• TCZ treatment significantly decreased ESR, CRP, TNF-α, IL-6, and DAS28 scores.
• Serum COMP levels showed a non-significant decrease after six months of TCZ treatment.
• A decrease in serum COMP levels was observed in both anti-TNF and anti-DMARD failure groups without significant difference.

Conclusions:

• TCZ therapy significantly reduces inflammation and disease activity in long-standing RA patients.
• TCZ may have a positive effect on cartilage joint destruction, indicated by a trend in COMP level decrease.
• The findings suggest TCZ's potential benefit in managing RA, particularly in patients with prior treatment failures.